GLP-3R (often referring to triple agonists targeting GLP-1, GIP, and Glucagon receptors) represents the cutting edge of metabolic peptide research. By agonizing three distinct incretin/metabolic receptors simultaneously, these compounds exhibit synergistic effects on energy homeostasis.
### Mechanisms of Action
* **GLP-1 Receptor:** Delays gastric emptying, increases glucose-dependent insulin secretion, and promotes satiety.
* **GIP Receptor:** Enhances insulin secretion and modulates lipid metabolism in adipose tissue.
* **Glucagon Receptor:** Increases energy expenditure and promotes lipolysis, counteracting the typical weight-loss plateau seen with GLP-1 alone.
### Research Applications
* **Obesity and Metabolic Syndrome:** Triple agonists consistently demonstrate superior weight loss and lipid profile improvements in animal models compared to dual or single agonists.
* **Hepatic Steatosis:** Research indicates significant reductions in liver fat and improvements in markers of non-alcoholic steatohepatitis (NASH).
*Disclaimer: GLP-3R is sold strictly for laboratory research use only. Not for human consumption.*